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ABSTRACT
Purpose: To directly compare parents’ perspectives of the quality of life of their
children with Spinal Muscular Atrophy (SMA) who received supportive care, nusinersen
(Spinraza®), onasemnogene abeparvovec-xioi (Zolgensma®), or both nusinersen and
onasemnogene abeparvovec-xioi. Methods: The parents of children with SMA were
recruited to complete anonymous online surveys. All surveys included qualitative
questions about quality of life. Surveys regarding children in the 1-12-month and 13-24month age groups included the Pediatric Quality of Life Infant Scales assessment.
Surveys regarding children in the 2-4-year age group included the Pediatric Quality of
Life Inventory 4.0 Generic Core Scales and the Pediatric Quality of Life 3.0
Neuromuscular Module assessments. The >4-year age group did not include a
quantitative quality of life assessment. Results: The 1-12-month age group average
physical quality of life summary score was increased for children treated with a
combination of both nusinersen and onasemnogene abeparvovec-xioi and also those
treated with onasemnogene abeparvovec-xioi only. The 1-12-month- age group average
psychosocial quality of life summary score was increased for children treated with
nusinersen only. Physical and psychosocial quality of life data regarding the 13-24-month
age group was not statistically significant. All surveys regarding the 2-4-year age group
and one survey from the >4-year age group were excluded to eliminate the possibility of
identifying participants. Conclusion: It was not possible to identify and associate a single
treatment with conferring a statistically higher quality of life; however, the quantitative
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and qualitative responses collected allowed for an inference that parents believe their
children with SMA have a greater quality of life when provided treatment over having
only supportive care. Before the FDA approval of the available treatments, healthcare
providers who shared the diagnosis of SMA with parents had to also share that there was
no known effective treatment. However, today when families hear the diagnosis of SMA,
they can be hopeful for their child and family’s future because of the treatments available
and the proven increase in quality of life with these treatments. Knowing how quality of
life perspectives differ based on the type of treatment received can help in the education
of parents of children with SMA.
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CHAPTER 1
INTRODUCTION
Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is the leading genetic cause of mortality in
infants with an incidence of approximately one in every eleven thousand livebirths (Kolb
et al., 2017; Vaidya & Boes, 2018). SMA is an autosomal recessive disease characterized
by alpha motor neuron degeneration in the anterior horn of the spinal cord, skeletal
muscle atrophy, and generalized weakness involving the limbs, bulbar and respiratory
muscles (Chiriboga et al., 2016; Wirth, Karakaya, Kye, & Mendoza-Ferreira, 2020).
There are five types of SMA that can be historically classified based on age of
symptom onset and achieved motor abilities (Rao, Kapp, & Schroth, 2018; Vaidya &
Boes, 2018; Wirth et al., 2020). SMA type zero is the most severe and is characterized by
symptom onset in utero and death soon after birth. SMA type I, also known as WerdnigHoffman disease, is the most common type with symptom onset before six months of age
and without substantial treatment, a two-year life expectancy. Individuals with SMA type
I typically have severe hypotonia, difficulty breathing, poor suck, and are unable to sit
independently (Lunn & Wang, 2008). Individuals with SMA type II typically have onset
of symptoms between six to eighteen months of age. They are able to sit without support,
although they may not retain this skill, and they are not able to walk, have generalized
muscle weakness, and many develop kyphoscoliosis (Lunn & Wang, 2008). SMA type
III, also known as Kugelberg-Welander disease, is characterized by the onset of
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symptoms after eighteen months of age. Individuals with SMA type III may be able to sit
and walk independently, although they may not retain these skills, and many develop
scoliosis (Lunn & Wang, 2008). Individuals with SMA type IV have onset of symptoms
in adulthood and typically have mild motor impairment and respiratory problems (Lunn
& Wang).
Genetic Basis of SMA
SMA is caused by homozygous loss of function mutations in the survival motor
neuron one (SMN1) gene that encodes the survival motor neuron (SMN) protein (Finkel
at al., 2016). The function of the SMN protein is not completely understood; however, its
primary role is thought to be in snRNP biogenesis and splicing (Wirth et al., 2020). A
similar gene, survival motor neuron two (SMN2), has a coding sequence identical to that
of the SMN1 gene, except for five nucleotides (Wirth et al, 2020). Specifically, a C to T
substitution within exon seven of SMN2 (c.840C>T) causes this exon to be spliced out of
SMN2 mRNA transcripts 90% of the time, resulting in an unstable SMN protein that is
rapidly degraded instead of the full-length SMN protein. It is estimated that a full-length
SMN protein results from SMN2 approximately 10% of the time as about 10% of SMN2
mRNA transcripts include exon seven (Helmken et al., 2003; Lefebvre et al., 1995). The
number of copies of SMN2 generally explains the phenotypic variability between the
different types of SMA. Approximately 80% of type I individuals have one or two SMN2
copies, 82% of type II individuals have three copies, and about 50%-61% of individuals
with type III and 75% of individuals with type IV have four copies (Calucho et al., 2018;
Feldkötter, Schwarzer, Wirth, Weinker, & Wirth, 2002; Wirth et al., 2006). The more
copies of SMN2 an individual has, the more SMN protein they produce. Those with a
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small amount of full-length SMN protein typically have more severe symptoms, and
those with more full-length SMN protein typically have less severe symptoms (Chiriboga
et al., 2016; Feldkötter et al., 2002; Finkel et al., 2016; Mailman et al., 2002; Wirth et al.,
2006).
Medical Management for Individuals with SMA
Treatment with Nusinersen
On December 23, 2016 the Food and Drug Administration (FDA) approved
nusinersen (Spinraza®) as the first treatment for individuals with all types of SMA (Hoy,
2017). Nusinersen is an antisense oligonucleotide delivered through repeated intrathecal
injections (Finkel et al., 2016). Treatment with nusinersen includes three 12mg loading
doses given fourteen days apart with a fourth 12mg dose given thirty days after the third
loading dose. Continued treatment with nusinersen includes an additional 12mg dose
every four months for life (Hoy, 2017). Nusinersen functions by altering the splicing of
SMN2 to promote the inclusion of exon seven in SMN2 mRNA transcripts, thereby
increasing the amount of full-length SMN protein produced (Kolb et al., 2017).
Treatment with nusinersen costs approximately $400,000-500,000 in the first year and
$250,000-300,000 per year thereafter for the duration of the treated individual’s lifetime
(Wirth et al., 2020).
In a randomized, double-blind clinical trial (ENDEAR), 122 infants with SMA
type I aged 210 days or younger with two SMN2 copies were treated with 12mg
nusinersen or a sham-procedure. Those treated with nusinersen had a lower risk of death
and were more likely to reach a motor milestone (i.e., head control, ability to roll, sitting
without assistance, and standing) than those who received the sham-procedure. Adverse
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reactions reported (i.e., constipation, lower and upper respiratory tract infections) were
present for both the group treated with nusinersen and the group given the shamprocedure (Finkel et al., 2017). From this data it was concluded that early treatment with
nusinersen may be necessary to maximize response outcomes. In a separate randomized,
double-blind clinical trial (CHERISH), 12mg nusinersen or a sham-procedure was given
to 126 children with SMA types II and III with onset of symptoms after six months of
age. In this study, children treated with nusinersen showed definite motor improvement
and higher probability of survival than the children given the sham-procedure (Mercuri et
al, 2018a). Individuals who participated in ENDEAR and CHERISH clinical trials were
enrolled in an open-label phase III clinical trial designed to evaluate the long-term safety
and tolerability of 12mg of nusinersen (SHINE). An interim evaluation of SHINE data
showed that treatment with nusinersen is safe and well tolerated (Maharshi & Hasan,
2017; Wirth et al., 2020).
In an open-label clinical trial (NURTURE), 25 infants six weeks or younger with
genetically diagnosed presymptomatic SMA and two or three SMN2 copies were treated
with 12mg nusinersen. All of these infants were living, and none needed respiratory
intervention after day 64 of treatment. Infants from this trial who were treated with
nusinersen but then passed away were found on autopsy to have increased SMN2 mRNA
exon seven inclusion and increased SMN protein in the spinal cord compared to
individuals with SMA who did not receive nusinersen (De Vivo et al, 2019; Finkel et al.,
2016). Published interim efficacy and safety outcomes from this clinical trial showed that
the infants (now children) treated with nusinersen were living past the age of expected
symptom onset. Additionally, 100% could sit without support, 92% could walk without
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assistance, and 88% could walk independently. From this data it was concluded that
treatment with nusinersen as soon as possible after a genetic diagnosis of SMA is
established is of extreme importance (De Vivo et al., 2019).
Treatment with Onasemnogene abeparvovec-xioi
On May 24, 2019 the FDA approved onasemnogene abeparvovec-xioi
(Zolgensma®) as a second treatment for patients with SMA type I under two years of age
(Hoy, 2019). It consists of adeno-associated virus nine, which is modified to include a
functional copy of the SMN1 gene (Hoy, 2019). Introducing a functional copy of the
SMN1 gene into an affected person’s motor neuron cells addresses the genetic cause of
SMA and increases the amount of SMN protein present in the body (Mendell et al.,
2017). The dosing of onasemnogene abeparvovec-xioi is 1.1 × 1014 vector genomes/kg
body weight administered over 60 minutes as a single intravenous infusion. Treatment
with a single injection of onasemnogene abeparvovec-xioi costs two million US dollars
(Wirth et al., 2020).
Fifteen infants with confirmed SMA type I and two copies of SMN2 under the age
of six months were enrolled in a phase I open-label clinical trial (START) where 12
infants were treated with a high dose of onasemnogene abeparvovec-xioi (2.0 x 1014
vector genomes/kg body weight) and three infants were treated with a lower dose (6.7 x
1013 vector genomes/kg body weight). Compared to historical cohorts of untreated infants
with SMA, infants in this study treated with onasemnogene abeparvovec-xioi showed
improved motor function and improved achievement of motor milestones such as sitting
without support, rolling over, feeding orally, speaking, and walking independently.
Additionally, it was shown that infants who received the higher dose of onasemnogene
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abeparvovec-xioi before three months of age had improved motor function and improved
motor milestone achievement earlier than those who also received the higher dose, but
not until they were three months of age or older. A side effect observed was that infants’
liver transaminase levels were increased significantly, a finding which was hypothesized
to be a consequence of a massive immune response against viral peptides; however, this
was successfully controlled by daily glucocorticoid administration for one-month post
treatment (Mendell et al., 2017). At 24 months follow-up, infants in this study showed a
reduced amount of pulmonary interventions, stable or improved swallow function,
sustainment of achieved motor function and milestones, and decreased hospitalization
rate compared to historical cohorts. It was suggested that the reduction in healthcare
utilization observed with onasemnogene abeparvovec-xioi treatment might alleviate
patient and caregiver burden and could be associated with an improved quality of life
(Al-Zaidy et al., 2019; Shell et al., 2019; Mendell et al., 2019). The long-term follow-up
START results are supported by the open-label phase III clinical trial (STR1VE) where
22 infants under the age of six months with SMA type I and one or two copies of SMN2
were treated with onasemnogene abeparvovec-xioi and found to have rapid
improvements in motor function that suggested future improvements in achievement of
motor milestones and survival (Shell et al., 2019).
In an open-label phase I dose-escalation clinical trial (STRONG), individuals with
SMA type II and three copies of SMN2 were treated with onasemnogene abeparvovecxioi. In total, three patients aged >6 to <24 months were treated with 6.0 X 10^13 vector
genomes/kg body weight onasemnogene abeparvovec-xioi and thirteen patients aged >6
to <24 months were treated with 1.2 X 10^14 vector genomes/kg body weight of
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onasemnogene abeparvovec-xioi. An additional five patients aged >24 to <60 months
were treated with 1.2 X 10^14 vector genomes/kg body weight of onasemnogene
abeparvovec-xioi. All treated individuals showed a gain in motor milestones achieved
(i.e., rolling from back to sides, standing without support, walking without support) and
there were no safety or tolerability concerns regarding the onasemnogene abeparvovecxioi (Finkel et al., 2019).
Finally, in an open-label phase III clinical trial (SPR1NT) individuals with
presymptomatic SMA and two or three copies of SMN2 were treated with onasemnogene
abeparvovec-xioi. These presymptomatic individuals showed age-appropriate
achievement of motor milestones and motor function after treatment (Schultz et al.,
2019).
Nusinersen vs. Onasemnogene abeparvovec-xioi
Dabbous et al. (2019) indirectly compared previously published data about infants
with SMA Type I and two copies of SMN2 treated with nusinersen in the ENDEAR
clinical trial to data about infants with SMA Type I and two copies of SMN2 treated with
onasemnogene abeparvovec-xioi in the START clinical trial. Looking at the overall
survival for these infants, Dabbous et al. concluded that the likelihood of preventing
death was 20% higher for those treated with onasemnogene abeparvovec-xioi. They also
concluded that infants treated with onasemnogene abeparvovec-xioi might have more
independence from permanent ventilation, improved motor function, and an increase in
the number of motor milestones achieved than infants treated with nusinersen. They
recommend long-term monitoring of patients treated with onasemnogene abeparvovecxioi to confirm these conclusions.
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Supportive Care
If an individual with SMA is not treated with nusinersen or onasemnogene
abeparvovec-xioi, supportive care may be used to manage the clinical course of the
disease. Respiratory support involves medications and techniques that mechanically
enhance a patient’s cough for the clearance of respiratory secretions (Kolb et al., 2017).
Additionally, hypoventilation is prevented with devices that increase ventilation during
sleep or periods of illness (Kolb et al., 2017). Nutritional support includes interventions
to control gastroesophageal reflux, improve digestion, and minimize constipation. For
patients with poor suck and swallowing issues, in addition to speech and feeding therapy,
the use of a nasogastric tube or surgically placed feeding tube may be necessary (DiVito
& Konek, 2010; Mercuri et al., 2018b). Physical therapy, occupational therapy, and
bracing are used to prevent and treat contractures and scoliosis. Furthermore, some
patients require surgery for internal spinal fixation (Iannaccone, 2007; Mercuri et al.,
2018b; Wang et al, 2007).
Quality of Life
Definition
Vaidya and Boes (2018) define quality of life as “an individual’s perception of
their position in life in the context of the culture and value systems in which they live and
in relation to their goals, expectations, standards, and concerns” and state it is important
to take into account when assessing a patient’s overall health. They also define healthrelated quality of life as “the degree to which a medical condition impacts the physical,
emotional, and social well-being of an individual” (Vaidya & Boes, 2018). For the
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purpose of this literature review, quality of life and health-related quality of life are used
as an interchangeable concept.
Evaluating Quality of Life Within SMA
The two instruments used most frequently in SMA quality of life research are the
Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL GCS) and the
Pediatric Quality of Life 3.0 Neuromuscular Module (PedsQL NMM). Therefore, this
review of the present literature excludes studies that evaluate quality of life of children
with SMA using other measurement tools. Additionally, because the present study is
about the quality of life of children treated with nusinersen, onasemnogene abeparvovecxioi, both nusinersen and onasemnogene abeparvovec-xioi, or supportive care, studies
that evaluate the quality of life of children with SMA treated with other experimental
medications are excluded from this literature review. The PedsQL GCS measures health
related quality of life in healthy populations and populations where patients have acute or
chronic health conditions. It contains questions about physical, emotional, social, and
school functioning. The PedsQL NMM measures health related quality of life in patients
with neuromuscular diseases. It contains questions about the patient’s neuromuscular
disease and ability to communicate as well as questions regarding family resources. Both
instruments allow for patient self-assessment (PSA) and caregiver proxy-assessment
(CPA). Table 1.1 contains information about previous research completed regarding the
quality of life of children with SMA that use the PedsQL GCS and/or the PedsQL NMM.
These studies consistently show that children with SMA have an impaired quality of life.
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Rationale
The quality of life of children with SMA has been investigated previously;
however, there is no apparent literature published that directly compares parents’
perspectives of the quality of life of their children with SMA who received supportive
care, nusinersen, onasemnogene abeparvovec-xioi, and those treated with a combination
of both nusinersen and onasemnogene abeparvovec-xioi.
Committee Opinion Number 691, “Carrier Screening for Genetic Conditions”,
published by the American College of Obstetricians and Gynecologists (ACOG) in
conjunction with the addition of SMA to the Recommended Uniform Screening Panel
(RUSP), which is used as a guideline for state universal newborn screening programs, is
support for the present study. ACOG (2017) recommends the following:
Screening for spinal muscular atrophy should be offered to all women who are
considering pregnancy or are currently pregnant. In patients with a family history
of spinal muscular atrophy, molecular testing reports of the affected individual
and carrier testing of the related parent should be reviewed, if possible, before
testing. If the reports are not available, SMN1 deletion testing should be
recommended for the low-risk partner. (p. 2)
It is important for genetic counselors, genetic professionals, and other healthcare
providers to be knowledgeable regarding parents’ perspectives of the quality of life of
their children with SMA who have received supportive care, nusinersen, onasemnogene
abeparvovec-xioi, and those treated with both nusinersen and onasemnogene
abeparvovec-xioi. Knowing how quality of life perspectives differ based on the type of
treatment received can help genetics professionals educate parents who are found to be
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carriers for SMA and are at risk of having an affected child, or who have a child that has
been diagnosed with SMA. Additionally, quality of life research helps to inform about
the implications of disease on the patient and the patient’s family.
Purpose
The aim of the present study is to directly compare parents’ perspectives
regarding the quality of life of their children with SMA, both living and deceased, who
received or are currently receiving supportive care, nusinersen, onasemnogene
abeparvovec-xioi, or treatment with both nusinersen and onasemnogene abeparvovecxioi. We predict that parents of children with SMA who received or are currently
receiving treatment with nusinersen and/or onasemnogene abeparvovec-xioi will score
their children’s quality of life higher than parents whose children received or are
currently receiving only supportive care.
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Table 1.1 Previous Research Investigating the Quality of Life of Individuals with SMA
Table adapted from (Landfeldt et al., 2019). Studies that used instruments other than the PedsQL GCS and PedsQL NMM and studies
that evaluated experimental medications other than nusinersen and onasemnogene abeparvovec-xioi were excluded.
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Authors (Year)

Patient Sample

Instrument(s)
(PSA and CPA)

Iannaccone, Hynan &
Group, 2003

33 US patients

PedsQL NMM

Iannaccone et al.,
2009

125 US patients

PedsQL NMM
PedsQL GCS

Kaufmann et al.,
2012

57 US patients with type II or
III

PedsQL GCS

Kocova, Dvorackova,
Vondracek, &
Haberlova, 2014

35 Czech patients; 11% type I,
66% type II, and 23% type III

PedsQL NMM

Klug et al., 2016

189 German patients; 6% type
I, 39% type II, and 55% type III

PedsQL NMM

Chiriboga et al, 2016

28 US patients; 54% type II and
46% type III

PedsQL NMM
PedsQL GCS

Main Finding(s)
Patients had impaired quality of life across all
instrument domains.
Patients had impaired quality of life across all
instrument domains. Agreement between PSAs
and CPAs was moderate to poor.
Patients had impaired quality of life across all
instrument domains. Instrument scores were
markedly different across SMA type.
Patients had impaired quality of life across all
instrument domains, and lower scores compared
with US reference data.
Patient quality of life was impaired across all
instrument domains and inversely associated with
SMA type.
No statistically significant changes in quality of
life scores observed for patients given nusinersen.

CHAPTER 2
QUALITY OF LIFE OF CHILDREN WITH SPINAL MUSCULAR ATROPHY:
PARENTS’ PERSPECTIVES IN LIGHT OF NEW TREATMENTS 1

1Tallas,

A. Zvejnieks, D., Brook, S., & Engelstad, K. To be submitted to Journal of
Genetic Counseling.
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Abstract
Purpose: To directly compare parents’ perspectives of the quality of life of their
children with Spinal Muscular Atrophy (SMA) who received supportive care, nusinersen
(Spinraza®), onasemnogene abeparvovec-xioi (Zolgensma®), or both nusinersen and
onasemnogene abeparvovec-xioi. Methods: The parents of children with SMA were
recruited to complete anonymous online surveys. All surveys included qualitative
questions about quality of life. Surveys regarding children in the 1-12-month and 13-24month age groups included the Pediatric Quality of Life Infant Scales assessment.
Surveys regarding children in the 2-4-year age group included the Pediatric Quality of
Life Inventory 4.0 Generic Core Scales and the Pediatric Quality of Life 3.0
Neuromuscular Module assessments. The >4-year age group did not include a
quantitative quality of life assessment. Results: The 1-12-month age group average
physical quality of life summary score was increased for children treated with a
combination of both nusinersen and onasemnogene abeparvovec-xioi and also those
treated with onasemnogene abeparvovec-xioi only. The 1-12-month- age group average
psychosocial quality of life summary score was increased for children treated with
nusinersen only. Conclusion: It was not possible to identify and associate a single
treatment with conferring a statistically higher quality of life; however, the quantitative
and qualitative responses collected allowed for an inference that parents believe their
children with SMA have a greater quality of life when provided treatment over having
only supportive care. Before the FDA approval of the available treatments, healthcare
providers who shared the diagnosis of SMA with parents had to also share that there was
no known effective treatment. However, today when families hear the diagnosis of SMA,
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they can be hopeful for their child and family’s future because of the treatments available
and the proven increase in quality of life with these treatments. Knowing how quality of
life perspectives differ based on the type of treatment received can help in the education
of parents of children with SMA.
Introduction
Spinal Muscular Atrophy (SMA) is the leading genetic cause of mortality in
infants (Vaidya & Boes, 2018). SMA is an autosomal recessive disease characterized by
spinal cord motor neuron degeneration, skeletal muscle atrophy, and generalized
weakness involving the limbs, bulbar, and respiratory muscles (Chiriboga et al, 2016;
Wirth et al., 2020). There are five types of SMA that can be historically classified based
on age of symptom onset and achieved motor abilities (Rao et al., 2018; Vaidya & Boes,
2018; Wirth et al., 2020).
SMA is caused by homozygous loss of function mutations in the survival motor
neuron one (SMN1) gene that encodes the survival motor neuron (SMN) protein (Finkel
at al., 2016). A similar gene, survival motor neuron two (SMN2), has a coding sequence
identical to that of the SMN1 gene, except for five nucleotides (Wirth et al, 2020).
Specifically, a C to T substitution within exon seven of SMN2 (c.840C>T) causes this
exon to be spliced out of SMN2 mRNA transcripts 90% of the time, resulting in an
unstable SMN protein that is rapidly degraded instead of the full-length SMN protein. It
is estimated that a full-length SMN protein results from SMN2 approximately 10% of the
time as about 10% of SMN2 mRNA transcripts include exon seven (Helmken et al., 2003;
Lefebvre et al., 1995). The number of copies of SMN2 generally explains the phenotypic
variability between the different types of SMA. The more copies of SMN2 an individual
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has, the more SMN protein they produce. Those with a small amount of full-length SMN
protein typically have more severe symptoms, and those with more full-length SMN
protein typically have less severe symptoms (Chiriboga et al., 2016; Feldkötter et al,
2002; Finkel et al., 2016; Mailman et al, 2002; Wirth et al., 2006).
Treatments for SMA
Nusinersen (Spinraza®) was the first FDA approved treatment for individuals with
all types of SMA (Hoy, 2017). Nusinersen is an antisense oligonucleotide delivered
through repeated intrathecal injections (Finkel et al., 2016). Treatment with nusinersen
includes three 12mg loading doses given fourteen days apart with a fourth 12mg dose
given thirty days after the third loading dose. Continued treatment with nusinersen
includes an additional 12mg dose every four months for life (Hoy, 2017). Nusinersen
functions by altering the splicing of SMN2 to promote the inclusion of exon seven in
SMN2 mRNA transcripts, thereby increasing the amount of full-length SMN protein
produced (Kolb et al., 2017). Treatment with nusinersen costs approximately $400,000500,000 in the first year and $250,000-300,000 per year thereafter for the duration of the
treated individual’s lifetime (Wirth et al., 2020).
Onasemnogene abeparvovec-xioi (Zolgensma®) was the second FDA approved
treatment for patients with SMA type I under two years of age (Hoy, 2019). It consists of
adeno-associated virus nine, which is modified to include a functional copy of the SMN1
gene (Hoy, 2019). Introducing a functional copy of the SMN1 gene into an affected
person’s motor neuron cells addresses the genetic cause of SMA and increases the
amount of SMN protein present in the body (Mendell et al., 2017). The dosing of
onasemnogene abeparvovec-xioi is 1.1 × 1014 vector genomes/kg body weight
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administered over 60 minutes as a single intravenous infusion. Treatment with a single
injection of onasemnogene abeparvovec-xioi costs two million US dollars (Wirth et al.,
2020).
Dabbous et al. (2019) indirectly compared previously published data about infants
with SMA Type I and two copies of SMN2 treated with nusinersen in the ENDEAR
clinical trial to data about infants with SMA Type I and two copies of SMN2 treated with
onasemnogene abeparvovec-xioi in the START clinical trial. Looking at the overall
survival for these infants, Dabbous et al. concluded that the likelihood of preventing
death was 20% higher for those treated with onasemnogene abeparvovec-xioi. They also
concluded that infants treated with onasemnogene abeparvovec-xioi might have more
independence from permanent ventilation, improved motor function, and an increase in
the number of motor milestones achieved than infants treated with nusinersen. They
recommend long-term monitoring of patients treated with onasemnogene abeparvovecxioi to confirm these conclusions.
If an individual with SMA is not treated with nusinersen or onasemnogene
abeparvovec-xioi, supportive care may be used to manage the clinical course of the
disease. Respiratory support involves medications and techniques that mechanically
enhance a patient’s cough for the clearance of respiratory secretions (Kolb et al., 2017).
Additionally, hypoventilation is prevented with devices that increase ventilation during
sleep or periods of illness (Kolb et al., 2017). Nutritional support includes interventions
to control gastroesophageal reflux, improve digestion, and minimize constipation. For
patients with poor suck and swallowing issues, in addition to speech and feeding therapy,
the use of a nasogastric tube or surgically placed feeding tube may be necessary (DiVito
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& Konek, 2010; Mercuri et al., 2018b). Physical therapy, occupational therapy, and
bracing are used to prevent and treat contractures and scoliosis. Furthermore, some
patients require surgery for internal spinal fixation (Iannaccone, 2007; Mercuri et al.,
2018b; Wang et al., 2007).
Quality of Life
Vaidya and Boes (2018) define quality of life as “an individual’s perception of
their position in life in the context of the culture and value systems in which they live and
in relation to their goals, expectations, standards, and concerns” and state it is important
to take into account when assessing a patient’s overall health. They also define healthrelated quality of life as “the degree to which a medical condition impacts the physical,
emotional, and social well-being of an individual” (Vaidya & Boes, 2018). For the
purpose of this study, quality of life and health-related quality of life are used as an
interchangeable concept.
The two instruments used most frequently in SMA quality of life research are the
PedsQL GCS and the PedsQL NMM. The PedsQL GCS measures health related quality
of life in healthy populations and populations where patients have acute or chronic health
conditions. The PedsQL NMM measures health related quality of life in patients with
neuromuscular diseases. Previous research completed regarding the quality of life of
children with SMA using the PedsQL GCS and/or the PedsQL NMM consistently show
that children with SMA have an impaired quality of life (Landfeldt et al., 2019).
Rationale
The quality of life of children with SMA has been investigated previously;
however, there is no apparent literature published that directly compares parents’
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perspectives of the quality of life of their children with SMA who received supportive
care, nusinersen, onasemnogene abeparvovec-xioi, and those treated with a combination
of both nusinersen and onasemnogene abeparvovec-xioi.
Committee Opinion Number 691, “Carrier Screening for Genetic Conditions”,
published by the American College of Obstetricians and Gynecologists (ACOG) in
conjunction with the addition of SMA to the Recommended Uniform Screening Panel
(RUSP), which is used as a guideline for state universal newborn screening programs, is
support for the present study. ACOG (2017) recommends the following:
Screening for spinal muscular atrophy should be offered to all women who are
considering pregnancy or are currently pregnant. In patients with a family history
of spinal muscular atrophy, molecular testing reports of the affected individual
and carrier testing of the related parent should be reviewed, if possible, before
testing. If the reports are not available, SMN1 deletion testing should be
recommended for the low-risk partner. (p. 2)
It is important for genetic counselors, genetic professionals, and other healthcare
providers to be knowledgeable regarding parents’ perspectives of the quality of life of
their children with SMA who have received supportive care, nusinersen, onasemnogene
abeparvovec-xioi, and those treated with both nusinersen and onasemnogene
abeparvovec-xioi. Knowing how quality of life perspectives differ based on the type of
treatment received can help genetics professionals educate parents who are found to be
carriers for SMA and are at risk of having an affected child, or who have a child that has
been diagnosed with SMA. Additionally, quality of life research helps to inform about
the implications of disease on the patient and the patient’s family.

19

Purpose
The aim of the present study is to directly compare parents’ perspectives
regarding the quality of life of their children with SMA, both living and deceased, who
received or are currently receiving supportive care, nusinersen, onasemnogene
abeparvovec-xioi, or treatment with both nusinersen and onasemnogene abeparvovecxioi. We predict that parents of children with SMA who received or are currently
receiving treatment with nusinersen and/or onasemnogene abeparvovec-xioi will score
their children’s quality of life higher than parents whose children received or are
currently receiving only supportive care.
Methods
Participants and Recruitment
The aim of this research was to directly compare parents’ perspectives regarding
the quality of life of their children with SMA. Therefore, participation was limited to the
parents of children with SMA. This study included parents of children who were
deceased in order to incorporate data from a population whose children might have only
received supportive care.
Recruitment for this study was conducted with the aid of the Gwendolyn Strong
Foundation (GSF), a non-profit dedicated to advocating for individuals and families with
SMA, supporting SMA research, and promoting inclusion for all people living with a
disability or genetic condition. The survey used was advertised through social media
postings on the GSF Facebook page and stories (https://www.facebook.com/endsma/),
Instagram account and stories (https://www.instagram.com/nevergiveuporg/), Twitter
account (https://twitter.com/nevergiveuporg), and website (https://nevergiveup.org)
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(Appendix A & Figure 2.1). Survey responses were recorded from August 21st, 2019 to
September 26th, 2019. To incentivize participation, individuals could enter a raffle to win
a $50 Amazon gift card and t-shirt from the GSF. In order to enter the raffle, participants
provided their email address that also served as their consent to be contacted if they were
selected as the winner. At the end of the survey period, all raffle entries were entered into
an online software which randomly selected a winner. To avoid coercion, we did not
provide any direct financial or academic compensation for participation in this study.
Participation in this study was voluntary. The survey welcome page detailed the
purpose of the study, eligibility requirements, and information addressing informed
consent (Appendix B). It was stated that participants could withdraw from the study at
any time by not completing all of the survey questions, and that informed consent was
provided upon completion of the survey. To establish participant eligibility and for
determination of the correct survey for participants to complete, there were several
screening questions at the beginning of the survey. Individuals who did not meet
participation eligibility were automatically directed to the end of the survey.
A total of 333 individuals attempted to complete the online survey. Thirty-four
individuals were excluded because they indicated they were not the parent of a child with
SMA. Two hundred ninety-nine individuals indicated that they were the parent of a child
with SMA and were directed to the next question. The next question asked participants if
their child with SMA was living or deceased in order to direct them to a tense appropriate
survey. If participants declined to answer this question, they were not allowed to move
forward to complete the survey. There were two participants that declined to answer this
question and were manually excluded from the study. An additional two survey responses
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were manually excluded because participants completed surveys that were not
appropriate for their child’s age. Furthermore, six surveys were also excluded because
participants did not complete greater than 50% of the quality of life assessment questions
that were necessary for the calculation of quality of life scores. Also, 58 incomplete
surveys were manually excluded as a completed survey was required for informed
consent. In total, 231 survey responses were included in the final analysis. Of the 231
responses, 206 were regarding living children, and 25 were regarding deceased children.
The survey exclusion process is summarized in Figure 2.2.
Instrument
Participants completed web-based surveys developed through Qualtrics.comXM.
Three quality of life instruments were used in this study. The first two instruments were
the PedsQL GCS and the PedsQL NMM (Iannaccone et al., 2009; Varni, Burwinkle,
Seid, & Skarr, 2003). They are quality of life instruments that have been validated with
SMA populations and are used most frequently in SMA quality of life research
(Iannaccone et al., 2009; Landfeldt et al., 2019). The PedsQL GCS contains questions
about physical, emotional, social, and school functioning. The PedsQL NMM contains
questions about the patient’s neuromuscular disease and ability to communicate as well
as questions regarding family resources. While both instruments allow for patient selfassessment (PSA) and caregiver proxy-assessment (CPA), they are only validated for
individuals over two years of age (Landfeldt et al., 2019). Due to the fact that
onasemnogene abeparvovec-xioi is only FDA approved for children under the age of two,
it was important that this study included an instrument that measured the quality of life of
children under the age of two. As there is no quality of life instrument validated for
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children with SMA who are younger than two years old, the third quality of life
instrument used in this study was the PedsQL Infant Scales (PedsQL IS) (Varni et al.,
2011). The PedsQL IS uses CPAs to measure health related quality of life in healthy
infants and infants who have acute or chronic health conditions. It contains questions
about physical symptoms and physical, emotional, social, and cognitive functioning.
There were eight separate but similar surveys available for participants to
complete (Appendices C-J). All of the surveys contained questions about the child’s
current age or age when he/she passed away, treatment(s) given, the number of copies of
SMN2 they have/had, etc. Surveys C, D, E, and F, regarding children <24 months of age,
were created using the PedsQL IS with permission from eProvide. Surveys C and D had a
reliability score of 0.894 and surveys E and F had a reliability score of 0.791. Surveys G
and H, regarding children in the 2-4-year age group, were created using the PedsQL GCS
and PedsQL NMM with permission from eProvide. Surveys I and J, regarding children
>4-years of age, did not include a published quality of life instrument because
onasemnogene abeparvovec-xioi is only FDA approved for children under the age of two
and considering the timing of this study and the approval of onasemnogene abeparvovecxioi it would be highly unlikely for children in this age group to have received this
treatment. Table 2.1 details the instruments used in each survey as well as the intended
participants for each survey.
Surveys utilized the appropriate tense for parents whose children were deceased.
For example, parents of a child who died would read, “How old was your child when
he/she passed away?” instead of reading, “How old is your child?”. Skip logic was
utilized to ensure participants received surveys that had the appropriate tense and were
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for the correct age of their child. Figures 2.3 - 2.6 show how many surveys were taken
about children in each age category and the type of treatments the children received.
Data Analysis
Qualtrics.comXM software was used to collect all data. The Scaling and Scoring of
the PedsQL published instructions were used in the analysis of the PedsQL IS, PedsQL
GCS, and PedsQL NMM instruments with permission from eProvide (Varni, 2017).
Microsoft® Excel and Laerd Statistics were used in the analysis of data. Statistical
analyses were reported in APA style. Alpha was calculated for scales C, D, E, and F. A
grounded theory approach was used to analyze the qualitative data collected from openended questions.
Results
Parent Reported Quality of Life of Children Aged 1-12 Months
A one-way Welch ANOVA was conducted to determine if parent proxy scores
regarding their children’s physical quality of life was different for those in the 1-12month age group treated with nusinersen, onasemnogene abeparvovec-xioi, both
nusinersen and onasemnogene abeparvovec-xioi, or supportive care. Participants were
classified into four groups: nusinersen only (n=10), onasemnogene abeparvovec-xioi only
(n=12), both nusinersen and onasemnogene abeparvovec-xioi (n=4), and supportive care
(n=17). The differences between the physical quality of life scores between these groups
were statistically significantly different, Welch’s F(3, 39) = 12.222, p < .001. Visual
analysis revealed that the mean physical quality of life summary score increased for
children treated with a combination of both nusinersen and onasemnogene abeparvovecxioi (M = 69.270, SD = 2.604) and those treated with onasemnogene abeparvovec-xioi
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only (M =70.937, SD = 1.145) compared to children treated with nusinersen only (M =
55.671, SD = 3.356), and those with supportive care (M = 55.458, SD = 11.916). The
average physical summary scores regarding children aged 1-12-months who received
different interventions is shown in Figure 2.7.
A second one-way Welch ANOVA was conducted to determine if parent proxy
scores regarding their children’s psychosocial quality of life was different for those in the
1-12-month age group treated with nusinersen, onasemnogene abeparvovec-xioi, both
nusinersen and onasemnogene abeparvovec-xioi, or supportive care. Participants were
classified into four groups: nusinersen only (n=10), onasemnogene abeparvovec-xioi only
(n=12), both nusinersen and onasemnogene abeparvovec-xioi (n=4), and supportive care
(n=17). The differences between the psychosocial quality of life scores between these
groups were statistically significantly different, Welch’s F(3, 39) = 12.163, p < .001.
Visual analysis revealed that the mean psychosocial quality of life summary score
increased for children treated with nusinersen only (M = 87.268, SD = 3.285) compared
to those treated with onasemnogene abeparvovec-xioi only (M = 68.914, SD = 9.1333),
both nusinersen and onasemnogene abeparvovec-xioi (M = 71.701, SD = 8.038), and
supportive care (M = 74.137, SD = 7.596). The average psychosocial summary scores
regarding children aged 1-12-months who received different interventions is shown in
Figure 2.8.
Parent Reported Quality of Life of Children Aged 13-24 Months
A one-way Welch ANOVA was conducted to determine if parent proxy scores
regarding their children’s physical quality of life was different for those in the 13-24month age group treated with nusinersen, onasemnogene abeparvovec-xioi, both
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nusinersen and onasemnogene abeparvovec-xioi, or supportive care. Participants were
classified into four groups: nusinersen only (n=12), onasemnogene abeparvovec-xioi only
(n=11), both nusinersen and onasemnogene abeparvovec-xioi (n=11), and supportive care
(n=5). The mean physical quality of life summary score increased for children treated
with both a combination of nusinersen and onasemnogene abeparvovec-xioi (M = 62.739
, SD = 12.487) and those treated with onasemnogene abeparvovec-xioi only (M = 65.517,
SD = 11.982) compared to children treated with nusinersen only (M = 58.492 , SD =
11.299) and those with supportive care (M = 54.444, SD = 9.305); however, the
differences between these groups were not statistically significant, Welch’s F(3,35 ) =
1.345 , p = .276. The average physical summary scores regarding children aged 13-24months who received different interventions is shown in Figure 2.9.
A final one-way Welch ANOVA was conducted to determine if parent proxy
scores regarding their children’s psychosocial quality of life was different for those in the
13-24-month age group treated with nusinersen, onasemnogene abeparvovec-xioi, both
nusinersen and onasemnogene abeparvovec-xioi, or supportive care. Participants were
classified into four groups: nusinersen only (n=12), onasemnogene abeparvovec-xioi only
(n=11), both nusinersen and onasemnogene abeparvovec-xioi (n=11), and supportive care
(n=5). The differences between the average psychosocial quality of life summary scores
for children treated with nusinersen only (M = 68.773, SD = 7.261), onasemnogene
abeparvovec-xioi only (M = 75.722, SD = 8.477), both nusinersen and onasemnogene
abeparvovec-xioi (M = 73.512, SD = 8.504), and supportive care (M = 71.076, SD =
12.897) were not statistically significant, Welch’s F(3, 35) = 1.309, p = .287. The average

26

psychosocial summary scores regarding children aged 13-24-months who received
different interventions is shown in Figure 2.10.
Parent Reported Quality of Life of Children Aged 2-4 Years
Of the 28 surveys taken about children with SMA in the 2-4-year age group, 26
were regarding children who received only nusinersen, one was about a child who
received onasemnogene abeparvovec-xioi only, and one was about a child who received
both nusinersen and onasemnogene abeparvovec-xioi. To eliminate the possibility of
identifying the one child who received onasemnogene abeparvovec-xioi only and the
other child who received both nusinersen and onasemnogene abeparvovec-xioi, all
quality of life data regarding children in the 2-4-year age group was not analyzed and is
not reported.
Parent Reported Quality of Life of Children Aged >4 Years
Of the 121 surveys taken about children with SMA in the >4-year age group, 22
were regarding children who received supportive care, 98 were about children who
received nusinersen, and one was about a child who received onasemnogene
abeparvovec-xioi only. To eliminate the possibility of identifying the one child in this age
group who received onasemnogene abeparvovec-xioi only, the survey about this child
was excluded from the data analysis. Qualitative quality of life responses regarding the
22 children who received supportive care and the 98 children who received nusinersen
were analyzed.
Qualitative Quality of Life Responses
In each survey parents were provided the opportunity to answer a free response
question and provide information about their children’s quality of life, the treatments, etc.
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Listed below are a few quotes from parents regarding the quality of life of their children
who received supportive care.
1. “He was unable to nurse after birth and a g-tube was placed shortly after. He was
excellent at following movements with his eyes, but shortly after birth lost his
moro reflex. He would cry if he had been held too long. He used his accessory
muscles to help breathe from birth and at 12 weeks had his first collapsed lung.”
2. “SMA took its natural course as far as progression goes. Despite following
dietary and respiratory protocols, she needed to be trached and lost all
movement.”
3. “My son passed away almost twelve years ago at nine months old. He was
diagnosed at six months old with SMA Type 1. His diagnosis was devastating. The
team of doctors at [hospital] said that he was showing symptoms for one of two
illnesses: Botulism or SMA. The same week he was treated for botulism and we
were told that if he were diagnosed with SMA, it would be unlikely for him to
reach his first birthday. I didn’t research the disease for those excruciating five
weeks while we waited for diagnosis results. I believed I saw improvement with
the help of physical therapy. Then we were given the grim diagnosis, no
treatment. No options. We were sent home, we loved on sweet little [name] in big
ways those next three months. Pneumonia became a chronic illness for him, and
we were placed on hospice and palliative care as patients on the pediatric floor
for just shy of three months. My son’s brave spirit and joy he shared with those
who knew him are forever cherished. Families today have hope with this
diagnosis. They have choices and options to improve their children’s quality of
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life and life expectancy. What a gift this research has been. From the bottom of
my heart, thank you.”
4. “There was no treatment available. Doctors told us we had six months with her
[and we should] take her home and love her. Regarding our genetic counseling
experience, frankly, it was worthless. My daughter attended the session and there
absolutely zero information gained from the appointment. It was a waste of time
and very disappointing. Thank you for your efforts in trying to improve this
area.”
Listed below are a few quotes from parents regarding the quality of life of their children
who received nusinersen (Spinraza®).
5. “Our child's natural disposition seems to be happy, social, [and] determined.
Coupled with treatment, it has helped us all stay positive.”
6. “[Name] has an excellent quality of life. [He] is a very positive child who loves
life, has many friends, and truly believes he can do everything.”
7. “My child has a wonderful quality of life and is one of the happiest persons I
know.”
8. “As parents, we can see improvement in his hands and arms after 4 doses.”
9. “[Name’s] quality of life has improved w[ith] Spinraza. He is able to sit up in his
chair longer and breathes better. He is also able to hold things in his hands, move
his legs, and move his head from side to side. He definitely tells us he feels like he
has more energy since starting Spinraza.”
10. “Before Spinraza we were in hospital a lot. Started Spinraza at 29 months and
he's now 48 months old. Since 29 months of age, we have had only two hospital
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admissions lasting 1-2 days each, compared to two-week admissions before
Spinraza. He has shown mostly respiratory improvements.”
11. “He has had 10 doses of Spinraza, and it has helped with lung function. Before
Spinraza cough sessions would take 2+ hours, now they only take 20 minutes!”
12. “My child’s quality of life has improved since starting Spinraza treatments. Her
stamina has improved, her voice is louder, her hand now has the stamina and
strength to play independently on her iPad for hours.”
13. “[Name] has been taking Spinraza for [a] year and a half. Although it may seem
like small gains, his voice is louder, his enunciation is better, he has a productive
cough, he has more stamina and is better able to drive his power chair. There are
many other feats that have improved as well.”
14. “Not having accessible transportation makes it difficult for us. She can’t be an
active member of our community.”
15. “Mobility, accessibility and acceptance are my biggest fears for [name].”
16. “With age I fear the lack of inclusiveness around her might not make her feel as
content as she now.”
17. “Dealing with her disease has been life-altering in every aspect I can think of. It
has been incredibly and profoundly difficult and has changed our family in ways
that are difficult to explain. [Name] has lived an incredible life...we have found
ways around her disability every opportunity we can. It is also been very
isolating. I feel that despite her physical limitations, she has lived a very happy
and amazing life.”
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18. “[Name] is a very energetic 5-year-old boy who loves everything about life.
Hates when people treat him like he is disabled! Loves aqua therapy, horses,
dinosaurs, [and] most of all playing soccer with his brother. Since starting
Spinraza [name] has been able to lift his legs off of the bed to do ‘kissing knees’
and has a new goal to be able to ride a bike very soon.”
Listed below are a few quotes from parents regarding the quality of life of their children
who received onasemnogene abeparvovec-xioi (Zolgensma®).
19. “Our child has maxed out the Chop-intend at 3 months of age and has met all
milestones so far, some even early. She is able to sit unassisted briefly and roll in
both directions. She is also able to pull herself toward objects. The only
indication of SMA symptoms presenting this far is slight aspiration on formula if
rice cereal is not added. She received treatment at 3 months old.”
20. “[Name] was treated with Zolgensma 7 days ago! We are already seeing new
strength in him!”
21. “He has an amazing quality of life. We keep him involved with anything an ablebodied person would do, just modified.”
Listed below are a few quotes from parents regarding the quality of life of their children
who received both nusinersen (Spinraza®) and onasemnogene abeparvovec-xioi
(Zolgensma®).
22. “The treatments have been amazing for my child.”
23. “Has made some movement gains.”

31

24. “Since starting Spinraza in April and then receiving Zolgensma in July, my son is
improving rapidly. He gained back the skills he lost and is now even starting to
stand with his braces/support.”
Discussion
In this study we set out to directly compare parents’ perspectives regarding the
quality of life of their children with SMA, both living and deceased, who received or are
currently receiving supportive care, nusinersen, onasemnogene abeparvovec-xioi, or
treatment with both nusinersen and onasemnogene abeparvovec-xioi. While the quality of
life of children with SMA has been investigated previously, there is no apparent literature
published that directly compares parents’ perspectives of the quality of life of their
children with SMA who have received these interventions. We predicted that parents of
children with SMA who received or are currently receiving treatment with nusinersen
and/or onasemnogene abeparvovec-xioi would score their children’s quality of life higher
than parents whose children received or are currently receiving only supportive care.
Considering the present data, it is not possible to identify and associate a single treatment
with conferring a statistically higher quality of life; however, the quantitative and
qualitative responses collected allow for an inference that parents believe their children
with SMA have a greater quality of life when provided treatment over having only
supportive care.
Physical Quality of Life
The physical quality of life summary scores regarding children in the 1-12-month
and 13-24-month age groups were an average of parents’ answers to questions about their
children’s physical symptoms and physical functioning. In the 1-12-month age group
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physical summary scores were increased, indicating greater quality of life, for children
treated solely with onasemnogene abeparvovec-xioi and for children treated with both
nusinersen and onasemnogene abeparvovec-xioi. Interestingly, while clinical trials have
proven the effectiveness of nusinersen on improving physical functioning and motor
abilities, children in this age group treated with nusinersen received low physical quality
of life summary scores that were equivalent to the scores regarding children who received
supportive care. Furthermore, while the differences between the physical quality of life
summary scores regarding children in the 13-24-month age group were not statistically
significant, it is important to note that for children in this age group, physical quality of
life scores followed the same pattern recorded for the 1-12-month age group (increased
for those treated with solely onasemnogene abeparvovec-xioi and also those treated with
both nusinersen and onasemnogene abeparvovec-xioi and low for children treated with
nusinersen and supportive care).
Considering these results, it may be that parents of children treated with
nusinersen in the 1-12-month and 13-24-month age groups were thinking about their
children’s adverse reactions to the treatment when completing the quality of life
assessment. Finkel et al. (2017) observed adverse reactions such as constipation and
respiratory tract infections in both patients treated with nusinersen and those given a
sham-procedure. Furthermore, parents of children treated with nusinersen in the 1-12month and 13-24-month age groups may believe their children have a lower physical
quality of life because of the repeated intrathecal injections required in the administration
of this treatment. It is important to consider that children treated with nusinersen in these
age groups would either be in their first year or would have just finished their first year of
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treatment that involves the highest number of intrathecal injections (three 12mg loading
doses given fourteen days apart, a fourth 12mg dose given thirty days after the third
loading dose, and continued treatment with a 12mg dose every four months). The
repeated intrathecal injections may also be the reason why parents of children in these
age groups treated with both nusinersen and onasemnogene abeparvovec-xioi scored their
children’s physical quality of life slightly lower than those treated with only
onasemnogene abeparvovec-xioi, which does not involve any intrathecal injections.
The qualitative responses from parents of children in the 1-12-month and 13-24month age groups treated with nusinersen are uninformative in terms of physical quality
of life as participants detailed their children’s diagnosis stories, their efforts for
onasemnogene abeparvovec-xioi to be covered by their children’s insurance, and their
appreciation for this study giving attention to the SMA community. The qualitative
responses from parents of children in the >4-year age group treated with nusinersen
however contradict the low physical quality of life scores recorded in the 1-12-month and
13-24-month age groups. Many parents of children in the >4-year age group shared that
since their children started nusinersen they had seen improvements in respiratory
function, motor abilities, and energy. Several participants also commented on a decrease
in the amount and length of hospitalizations their children had since starting nusinersen.
Al-Zaidy et al (2019) hypothesized that decreased hospitalizations of patients treated with
onasemnogene abeparvovec-xioi was associated with an alleviation of patient and
caregiver burden and could be associated with an improved quality of life, therefore we
hypothesize that decreased hospitalizations of children treated with nusinersen might also
be associated with an alleviation of patient and caregiver burden and could also be
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associated with an improved quality of life. The low physical quality of life scores
regarding children in the 1-12-month and 13-24-month age group and the lack of
qualitative responses regarding physical quality of life for these children leave us with the
hypothesis that the intrathecal injections necessary in the first year of treatment with
nusinersen is a large contributing factor in parents’ perspectives of their children’s
physical quality of life.
Psychosocial Quality of Life
The psychosocial quality of life summary scores regarding children in the 1-12month and 13-24-month age group were an average of parents’ answers to questions
about their children’s social, emotional, and cognitive functioning. Differences between
psychosocial summary scores regarding children in the 1-12-month age group were
statistically significant. Those treated solely with nusinersen had increased scores,
indicating greater quality of life, compared to those that received onasemnogene
abeparvovec-xioi only, both nusinersen and onasemnogene abeparvovec-xioi, and
supportive care. The differences between psychosocial summary scores regarding
children in the 13-24-month age group were not statistically significant and showed no
recognizable pattern.
At the time the survey became available to participants, onasemnogene
abeparvovec-xioi only had FDA approval for 3 months, compared to nusinersen that had
FDA approval for 32 months. Considering this difference, it is possible that parents of
children treated with onasemnogene abeparvovec-xioi had only seen an initial physical
improvement, because the treatment functions to directly increase the amount of SMN
protein in the body, and they might not have seen a psychosocial improvement yet at the
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time they completed the survey as psychosocial improvement may be related to one’s
ability to move and interact in the community and environment. This theory is supported
by the result that children treated with both nusinersen and onasemnogene abeparvovecxioi had slightly higher psychosocial quality of life scores compared to those that
received onasemnogene abeparvovec-xioi only.
It is important to note that two parent participants in the 1-12-month age group
whose children received onasemnogene abeparvovec-xioi provided feedback that the
quality of life assessment was difficult to complete. One parent stated that their child was
young at one month and three weeks of age, so some of the assessment items were not
applicable for them. They also stated that they did not realize they could skip questions
and attempted to go backwards in the survey to deselect items but were unable to. The
other parent stated that their child was six weeks old and received onasemnogene
abeparvovec-xioi at four weeks of age, so they believed some of the questions did not
apply to their child. After a review of the quality of life assessment these parents took, we
conclude that the questions that contribute the physical quality of life summary scores
apply equally to all children in the 1-12-month age group regardless of if they are 1
month or 12 months in age. Interestingly, we conclude that the questions that contribute
to the psychosocial quality of life summary scores do not apply equally to children that
are 1 month of age the same way that they apply to children that are 12 months of age.
We believe these two parents of children treated with onasemnogene abeparvovec-xioi
most likely scored their children lower on the psychosocial questions by indicating that
their children have trouble completing skills that they might not be expected to achieve
yet when considering their age and typical development (i.e. making eye contact,
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laughing, not imitating caregiver’s facial expressions and actions, etc.). Furthermore, it is
possible that other parents participating in this study had this experience but did not
provide feedback about it.
The Phrase “No Treatment” and Genetic Counseling
Nusinersen and onasemnogene abeparvovec-xioi were approved by the FDA as
the first two treatments for SMA in 2016 and 2019 respectively. Before these treatments
were available, individuals with SMA were provided supportive care for the management
of disease progression and symptoms. Several parents of children who received
supportive care shared about their heartbreak learning of the terminal diagnosis with no
treatment, the natural disease progression SMA had on their child, and the fact that
parents today are able to have hope because of the new treatments available. An example
of one of these quotes from a parent whose child was in the 1-12-month age group is
provided here:
My son passed away almost twelve years ago at nine months old. He was
diagnosed at six months old with SMA Type 1. His diagnosis was devastating. The
team of doctors at [hospital] said that he was showing symptoms for one of two
illnesses: Botulism or SMA. The same week he was treated for botulism and we
were told that if he were diagnosed with SMA, it would be unlikely for him to
reach his first birthday. I didn’t research the disease for those excruciating five
weeks while we waited for diagnosis results. I believed I saw improvement with
the help of physical therapy. Then we were given the grim diagnosis, no
treatment. No options. We were sent home, we loved on sweet little [name] in big
ways those next three months. Pneumonia became a chronic illness for him, and

37

we were placed on hospice and palliative care as patients on the pediatric floor
for just shy of three months. My son’s brave spirit and joy he shared with those
who knew him are forever cherished. Families today have hope with this
diagnosis. They have choices and options to improve their children’s quality of
life and life expectancy.
While the surveys available to take in this study did not include any questions regarding
parents’ genetic counseling experiences, one parent commented on the disappointing
experience their family had:
“There was no treatment available. Doctors told us we had six months with her
[and we should] take her home and love her. Regarding our genetic counseling
experience, frankly, it was worthless. My daughter attended the session and there
absolutely zero information gained from the appointment. It was a waste of time
and very disappointing.”
Before the FDA approval of nusinersen and onasemnogene abeparvovec-xioi, genetic
counselors, genetic professionals, and other healthcare providers who shared the
diagnosis of SMA with parents had to also share about the natural history of the disease
and that there was no known effective treatment. Yang et al. (2016) interviewed parents
of children with SMA type I and II who received supportive care before FDA’s approval
of nusinersen and onasemnogene abeparvovec-xioi to learn their experiences with
anticipatory loss. From these interviews it was found that parents of children with SMA
felt completely helpless because there was no known effective treatment; however, they
also felt pressure to provide their children the best care possible. They also learned that
parents initially seized every opportunity for exploratory treatments to extend their
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children’s lives, however, as treatments consistently failed, they decided to spend more
time cherishing their children’s brief lives using supportive care. However, today when
families hear the diagnosis of SMA, they will no longer be told that there is nothing they
can do and that they should take their children home and love them. Now, when a family
hears a diagnosis of SMA, they can be hopeful for their child and family’s future because
of the treatments available and the proven increase in quality of life with these
treatments. It is important for genetic counselors, genetic professionals, and other
healthcare providers to be knowledgeable about parents’ perspectives of the quality of
life of their children with SMA who have received the various treatments because
knowing how quality of life perspectives differ based on the type of treatment received
can help them educate parents who are found to be carriers for SMA and are at risk of
having an affected child, or who have a child that has been diagnosed with SMA. Data
collected in this study undoubtedly helps inform about parents’ perspectives of the
quality of life of their children with SMA who have received the various treatments.
Limitations and Future research
Due to the fact that onasemnogene abeparvovec-xioi is only FDA approved for
children under the age of two, it was important that this study included an instrument that
measured the quality of life of children in this age group, therefore the PedsQL IS was
utilized. A limitation of this study is that the PedsQL IS assessment has not been used in
SMA populations before, therefore we are not able to make a comparison of the data
collected in this study using this assessment to previously published studies. An
additional limitation of this study is that participants were only able to change, but not
deselect items in the quantitative quality of life assessments. This technical issue is
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important, because the questions in the PedsQL IS that contributed to the psychosocial
quality of life summary scores do not apply equally to children that are 1 month of age
the same way that they apply to children that are 12 months of age. We believe that at
least two parents of children in the 1-12-month age group treated with onasemnogene
abeparvovec-xioi scored their children lower on the psychosocial questions by indicating
that their children have trouble completing skills that they might not be expected to
achieve yet when considering their age and typical development (i.e. making eye contact,
laughing, not imitating caregiver’s facial expressions and actions, etc.). Another
limitation of this study is that data regarding the 2-4-year age group, which used the
PedsQL GCS and PedsQL NMM assessments previously used in SMA quality of life
research, was excluded to eliminate the possibility of identifying participants and
therefore comparisons to previously published quality of life data using these assessments
could not be made. Another limitation of this study is that within the data that was
statistically significant (the 1-12-month age group) there was a small sample size with ten
parents whose children had nusinersen only, twelve parents whose children had
onasemnogene abeparvovec-xioi only, four parents whose children had both nusinersen
and onasemnogene abeparvovec-xioi, and seventeen parents whose children had
supportive care. A greater sample size may have allowed for more robust data from the 112-month age group and statistically significant data from the 13-24-month age group
and may have also allowed for inclusion of the data from the 2-4-year age group.
Additionally, the free response qualitative quality of life question in each survey was too
vague. If we included more specific qualitative quality of life questions such as, “please
describe your child’s physical quality of life” and “please describe your child’s
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psychosocial quality of life”, we may have received more detailed information from
parents about their children’s quality of life. Furthermore, the quality of life of children
without SMA was not assessed as a control group, therefore, the quality of life of
children with SMA that received the various treatments could not be compared to the
quality of life of unaffected, healthy children. Finally, although the aim of this study was
to learn and directly compare parents’ perspectives of their children’s quality of life
considering the various treatments, it is important to note that parents’ perceptions may
be different from their children’s perceptions of their own quality of life as the affected
individuals.
This study undoubtedly contributes to our knowledge of parents’ perspectives of
the quality of life of their children with SMA who have received the various interventions
available. It also provides information about how quality of life perspectives differ based
on the type of intervention received. Because the PedsQL IS assessment used in this
study has not been used in SMA populations previously, we recommend this study be
repeated with a larger sample size to 1) determine if this is an appropriate quality of life
assessment for children with SMA and 2) provide replication data to compare with the
data we collected. We suggest this larger follow-up study be conducted in approximately
five years to allow for more time between when onasemnogene abeparvovec-xioi was
approved by the FDA and data collection. Also, as SMA is considered a progressive
disease, tracking how parent perspectives of their children’s quality of life changes over
time with the various treatments available may be informative. Finally, as more
individuals are diagnosed and treated for SMA, it may be beneficial to investigate genetic

41

counselors’, genetic professionals’, and other health care providers’ comfortability
discussing the treatments and quality of life information with parents.
Conclusion
The purpose of this study was to directly compare parents’ perspectives of the
quality of life of their children with SMA who received supportive care, nusinersen,
onasemnogene abeparvovec-xioi, or both nusinersen and onasemnogene abeparvovecxioi. While the quality of life of children with SMA has been investigated previously,
there is no apparent literature published that directly compares parents’ perspectives of
the quality of life of their children with SMA who have received these interventions. We
predicted that parents of children with SMA who received or are currently receiving
treatment with nusinersen and/or onasemnogene abeparvovec-xioi would score their
children’s quality of life higher than parents whose children received or are currently
receiving only supportive care. Considering the present data, it was not possible to
identify and associate a single treatment with conferring a statistically higher quality of
life; however, the quantitative and qualitative responses collected allowed for an
inference that parents believe their children with SMA have a greater quality of life when
provided treatment over having only supportive care. Before the FDA approval of
nusinersen and onasemnogene abeparvovec-xioi, genetic counselors, genetic
professionals, and other healthcare providers who shared the diagnosis of SMA with
parents had to also share that there was no known effective treatment. However, today
when families hear the diagnosis of SMA, they can be hopeful for their child and family’s
future because of the treatments available and the proven increase in quality of life with
these treatments. Knowing how quality of life perspectives differ based on the type of
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treatment received can help in the education of parents who are found to be carriers for
SMA and are at risk of having an affected child, or who have a child that has been
diagnosed with SMA.
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Table 2.1 Surveys Available for Participants to Take in the Present Study
The survey each participant took was dependent on if their child was living or deceased
and the current age of their child or the child’s age at death.
Survey

Child with SMA
Living or Deceased

Current Age of Child
or Age at Death

Instrument(s)
(CPAs)

D

Living

1-12 Months

PedsQL IS

E

Deceased

1-12 Months

PedsQL IS

F

Living

13-24 Months

PedsQL IS

G

Deceased

13-24 Months

PedsQL IS

H

Living

2-4 Years

PedsQL GCS
PedsQL NMM

I

Deceased

2-4 Years

PedsQL GCS
PedsQL NMM

J

Living

Older than 4 Years

None

K

Deceased

Older than 4 Years

None
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Figure 2.1 Participant Recruitment Social Media Image
This image was used in the social media post that recruited study participants.
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2 Participants declined to answer if their child
was living or deceased
Excluded
2 Participants did not complete the appropriate
survey for their child's age
Excluded

299 Participants were the
parent of a child with SMA
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333 Total Survey
Responses
34 Participants were not the
parent of a child with SMA
Excluded

6 Participants did not complete greater than 50%
of the quality of life assessment questions
Excluded
58 Participants did not provide informed consent
by completing the survey
Excluded
231 Survey responses included in the final data
analysis

Figure 2.2 Survey Exclusion Process
Out of 333 total survey responses, 231 met the inclusion criteria and were included in the final data analysis.
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Figure 2.3 Interventions Received by Children with SMA Aged 1-12 Months
In total, 43 of the 231 surveys included in the final data analysis regarded children who
were living and 1-12 months in age or deceased at 1-12 months of age.
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Figure 2.4 Interventions Received by Children with SMA Aged 13-24 Months
In total, 39 of the 231 surveys included in the final data analysis regarded children who
were living and 13-24 months in age or deceased at 13-24 months of age.

48

1
onasemnogene
abeparvovec-xioi

1
onasemnogene
abeparvovec-xioi
& nusinersen

26
nusinersen

Figure 2.5 Interventions Received by Children with SMA Aged 2-4 Years
In total, 28 of the 231 surveys included in the final data analysis regarded children who
were living and 2-4 years in age or deceased at 2-4 years of age.
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Figure 2.6 Interventions Received by Children with SMA Aged >4 years
In total, 121 of the 231 surveys included in the final data analysis regarded children who
were living and >4 years in age or deceased at >4 years of age.
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Figure 2.7 Average Physical Summary Scores Regarding Children with SMA Aged
1-12 Months
The average physical quality of life summary score increased for children treated with
both nusinersen and onasemnogene abeparvovec-xioi and those treated with
onasemnogene abeparvovec-xioi only compared to children treated with nusinersen only
and those with supportive care.
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Figure 2.8 Average Psychosocial Summary Scores Regarding Children with SMA
Aged 1-12 Months
The average psychosocial quality of life summary score increased for children treated
with nusinersen only compared to those treated with onasemnogene abeparvovec-xioi
only, both nusinersen and onasemnogene abeparvovec-xioi, or supportive care.
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Figure 2.9 Average Physical Summary Scores Regarding Children with SMA Aged
13-24 Months
The differences between the average physical quality of life summary scores for children
treated with nusinersen only, onasemnogene abeparvovec-xioi only, both nusinersen and
onasemnogene abeparvovec-xioi, and supportive care was not statistically significant.
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Figure 2.10 Average Psychosocial Summary Scores Regarding Children with SMA
Aged 13-24 Months
The differences between the average psychosocial quality of life summary scores for
children treated with nusinersen only, onasemnogene abeparvovec-xioi only, both
nusinersen and onasemnogene abeparvovec-xioi, and supportive care was not statistically
significant.
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CHAPTER 3
CONCLUSIONS
The purpose of this study was to directly compare parents’ perspectives of the
quality of life of their children with SMA who received supportive care, nusinersen,
onasemnogene abeparvovec-xioi, or both nusinersen and onasemnogene abeparvovecxioi. While the quality of life of children with SMA has been investigated previously,
there is no apparent literature published that directly compares parents’ perspectives of
the quality of life of their children with SMA who have received these interventions. We
predicted that parents of children with SMA who received or are currently receiving
treatment with nusinersen and/or onasemnogene abeparvovec-xioi would score their
children’s quality of life higher than parents whose children received or are currently
receiving only supportive care. Considering the present data, it was not possible to
identify and associate a single treatment with conferring a statistically higher quality of
life; however, the quantitative and qualitative responses collected allowed for an
inference that parents believe their children with SMA have a greater quality of life when
provided treatment over having only supportive care. Before the FDA approval of
nusinersen and onasemnogene abeparvovec-xioi, genetic counselors, genetic
professionals, and other healthcare providers who shared the diagnosis of SMA with
parents had to also share that there was no known effective treatment. However, today
when families hear the diagnosis of SMA, they can be hopeful for their child and family’s
future because of the treatments available and the proven increase in quality of life with

55

these treatments. Knowing how quality of life perspectives differ based on the type of
treatment received can help in the education of parents who are found to be carriers for
SMA and are at risk of having an affected child, or who have a child that has been
diagnosed with SMA.
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APPENDIX A
PARTICIPANT RECRUITMENT SOCIAL MEDIA TEXT
Calling all SMA parents! We need your help with a new research study. This
research could help inform doctors, genetic counselors, and other medical professionals
about our children and their quality of life. With treatments such as Spinraza and gene
therapy/Zolgensma, it’s important that the medical community knows about our
children's lives so that they can speak knowledgeably to parents facing a new diagnosis.
This study is being done by Analyssa Tallas, a graduate student in the genetic counseling
program at the University of South Carolina, who was inspired to go into this field
because of Gwendolyn's SMA diagnosis. She is passionate about making a difference and
has been an advocate for the SMA community for years. If you are the parent of a child
with SMA, both living or deceased, treatment or no treatment or a combination of
treatments, we hope you will participate. The survey will take approximately 15 minutes,
and if you participate you will be entered to win a $50 Amazon gift card and a t-shirt
from our NEVER GIVE UP. Shop! The link posted below will take you directly to
Analyssa’s survey. Thank you so much for helping to continue changing the future of
SMA. http://uofsc.co1.qualtrics.com/jfe/form/SV_3EsTV2zveCSmr9X
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APPENDIX B
PARTICIPANT RECRUITMENT LETTER
Dear Potential Participant,
You are invited to participate in a graduate research study focusing on parents’
perspectives of the quality of life of children with Spinal Muscular Atrophy (SMA). I am
a graduate student in the genetic counseling program at the University of South Carolina
School of Medicine. My research investigates parents’ perspectives of the quality of life
of children with SMA. This research could help inform medical professionals so that they
might be able to speak knowledgably about the parents’ perspectives of their child’s life.
You are eligible to participate in this study if you are the parent of a child with SMA.
You must be over 18 years of age and be able to read and write in English.
Your participation in this study is voluntary. By completing this survey, you are
consenting that you have read and understand this information. At any time, you may
withdraw from the study by not completing the survey. All responses gathered will be
kept anonymous and confidential. The results of this study might be published or
presented at academic meetings; however, participants will not be identified.
This survey should take approximately 15 minutes to complete. Participants who
complete the survey will have the option to enter into a raffle for a $50 amazon gift card
and a t-shirt from The Gwendolyn Strong Foundation. If you win, your prize will be sent
to you at a later date, after all data has been collected. The email you provide in order to
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enter the raffle will not be used for any other purposes beyond to send you the raffle prize
if you have won.
Thank you for your time and consideration to participate in this study. If you have
any questions regarding this research, you may contact me directly using the contact
information below. If you have any questions about your rights as a research participant,
you may contact the Office of Research Compliance at the University of South Carolina
at (803) 777-7095.
Sincerely,
Analyssa Tallas
Master’s Candidate in Genetic Counseling
Analyssa.Tallas@uscmed.sc.edu
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APPENDIX C
SURVEY FOR PARENTS WHOSE CHLD IS LIVING AND 1-12 MONTHS IN AGE
Are you the parent of a child with SMA?
If you are the parent of more than one child with SMA please take the survey 1 time for
each child.
Yes
No
We would like to provide you with questions that use the appropriate tense; is your child
with SMA living or deceased?
My child is living
My child is deceased
How old is your child? If your child is 24 months, please choose 13-24 months. If your
child is older than 24 months but still 2, please choose the 2-4 option.
1-12 months
13-24 months
2-4 years
My child is older than 4 years
How many copies of the SMN2 gene does your child have? _______
Please select the treatments(s) your child has received.
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec-xioi)
None of the above
If your child has not received either of these treatments, please select “none of the
above”.
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The PedsQL IS assessment was utilized in this survey. Permission granted by eProvide.
To confirm that you have completed the correct questionnaire, please enter your child’s
age.____
If you have additional information you would like us to know about your child, his/her
treatment(s), quality of life, etc. please use the space provided below. _______
As a token of our appreciation for taking this survey, we will have a raffle for a $50
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation.
If you are interested in entering the raffle, please enter your email below.
By providing your email you acknowledge that your answers to this survey may not be
anonymous. ____________________________.
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APPENDIX D
SURVEY FOR PARENTS WHOSE CHILD IS DECEASED AT 1-12 MONTHS OF
AGE
Are you the parent of a child with SMA?
If you are the parent of more than one child with SMA please take the survey 1 time for
each child.
Yes
No
We would like to provide you with questions that use the appropriate tense; is your child
with SMA living or deceased?
My child is living
My child is deceased
How old was your child when he/she passed away? If your child was 24 months, please
choose 13-24 months. If your child was older than 24 months but still 2, please choose
the 2-4 option.
1-12 months
13-24 months
2-4 years
My child was older than 4 years
How many copies of the SMN2 gene did your child have? _______
Please select the treatments(s) your child received.
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec-xioi)
None of the above
If your child did not receive either of these treatments, please select “none of the above”.
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The PedsQL IS assessment was utilized in this survey. Permission granted by eProvide.
To confirm that you have completed the correct questionnaire, please enter how old your
child was when he/she passed away. ____
If you have additional information you would like us to know about your child, his/her
treatment(s), quality of life, etc. please use the space provided below. _______
As a token of our appreciation for taking this survey, we will have a raffle for a $50
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation.
If you are interested in entering the raffle, please enter your email below.
By providing your email you acknowledge that your answers to this survey may not be
anonymous. ____________________________.
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APPENDIX E
SURVEY FOR PARENTS WHOSE CHILD IS LIVING AND 13-24 MONTHS IN AGE
Are you the parent of a child with SMA?
If you are the parent of more than one child with SMA please take the survey 1 time for
each child.
Yes
No
We would like to provide you with questions that use the appropriate tense; is your child
with SMA living or deceased?
My child is living
My child is deceased
How old is your child? If your child is 24 months, please choose 13-24 months. If your
child is older than 24 months but still 2, please choose the 2-4 option.
1-12 months
13-24 months
2-4 years
My child is older than 4 years
How many copies of the SMN2 gene does your child have? _______
Please select the treatments(s) your child has received.
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec-xioi)
None of the above
If your child has not received either of these treatments, please select “none of the
above”.
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The PedsQL IS assessment was utilized in this survey. Permission granted by eProvide.
To confirm that you have completed the correct questionnaire, please enter your child’s
age. ____
If you have additional information you would like us to know about your child, his/her
treatment(s), quality of life, etc. please use the space provided below. _______
As a token of our appreciation for taking this survey, we will have a raffle for a $50
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation.
If you are interested in entering the raffle, please enter your email below.
By providing your email you acknowledge that your answers to this survey may not be
anonymous. ____________________________.
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APPENDIX F
SURVEY FOR PARENTS WHOSE CHILD IS DECEASED AT 13-24 MONTHS OF
AGE
Are you the parent of a child with SMA?
If you are the parent of more than one child with SMA please take the survey 1 time for
each child.
Yes
No
We would like to provide you with questions that use the appropriate tense; is your child
with SMA living or deceased?
My child is living
My child is deceased
How old was your child when he/she passed away? If your child was 24 months, please
choose 13-24 months. If your child was older than 24 months but still 2, please choose
the 2-4 option.
1-12 months
13-24 months
2-4 years
My child was older than 4 years
How many copies of the SMN2 gene did your child have? _______
Please select the treatments(s) your child received.
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec-xioi)
None of the above

74

If your child did not receive either of these treatments, please select “none of the above”.
The PedsQL IS assessment was utilized in this survey. Permission granted by eProvide.
To confirm that you have completed the correct questionnaire, please enter how old your
child was when he/she passed away. ____
If you have additional information you would like us to know about your child, his/her
treatment(s), quality of life, etc. please use the space provided below. _______
As a token of our appreciation for taking this survey, we will have a raffle for a $50
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation.
If you are interested in entering the raffle, please enter your email below.
By providing your email you acknowledge that your answers to this survey may not be
anonymous. ____________________________.
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APPENDIX G
SURVEY FOR PARENTS WHOSE CHILD IS LIVING AND 2-4 YEARS IN AGE
Are you the parent of a child with SMA?
If you are the parent of more than one child with SMA please take the survey 1 time for
each child.
Yes
No
We would like to provide you with questions that use the appropriate tense; is your child
with SMA living or deceased?
My child is living
My child is deceased
How old is your child? If your child is 24 months, please choose 13-24 months. If your
child is older than 24 months but still 2, please choose the 2-4 option.
1-12 months
13-24 months
2-4 years
My child is older than 4 years
How many copies of the SMN2 gene does your child have? _______
Please select the treatments(s) your child has received.
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec-xioi)
None of the above
If your child has not received either of these treatments, please select “none of the
above”.
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The PedsQL GCS and PedsQL NMM assessments were utilized in this survey.
Permission granted by eProvide.
To confirm that you have completed the correct questionnaire, please enter your child’s
age. ____
If you have additional information you would like us to know about your child, his/her
treatment(s), quality of life, etc. please use the space provided below. _______
As a token of our appreciation for taking this survey, we will have a raffle for a $50
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation.
If you are interested in entering the raffle, please enter your email below.
By providing your email you acknowledge that your answers to this survey may not be
anonymous. ____________________________.
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APPENDIX H
SURVEY FOR PARENTS WHOSE CHILD IS DECEASED AT 2-4 YEARS OF AGE
Are you the parent of a child with SMA?
If you are the parent of more than one child with SMA please take the survey 1 time for
each child.
Yes
No
We would like to provide you with questions that use the appropriate tense; is your child
with SMA living or deceased?
My child is living
My child is deceased
How old was your child when he/she passed away? If your child was 24 months, please
choose 13-24 months. If your child was older than 24 months but still 2, please choose
the 2-4 option.
1-12 months
13-24 months
2-4 years
My child was older than 4 years
How many copies of the SMN2 gene did your child have? _______
Please select the treatments(s) your child received.
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec-xioi)
None of the above
If your child did not receive either of these treatments, please select “none of the above”.
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The PedsQL GCS and PedsQL NMM assessments were utilized in this survey.
Permission granted by eProvide.
To confirm that you have completed the correct questionnaire, please enter how old your
child was when he/she passed away. ____
If you have additional information you would like us to know about your child, his/her
treatment(s), quality of life, etc. please use the space provided below. _______
As a token of our appreciation for taking this survey, we will have a raffle for a $50
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation.
If you are interested in entering the raffle, please enter your email below.
By providing your email you acknowledge that your answers to this survey may not be
anonymous. ____________________________.
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APPENDIX I
SURVEY FOR PARENTS WHOSE CHILD IS LIVING AND OLDER THAN 4
YEARS OF AGE
Are you the parent of a child with SMA?
If you are the parent of more than one child with SMA please take the survey 1 time for
each child.
Yes
No
We would like to provide you with questions that use the appropriate tense; is your child
with SMA living or deceased?
My child is living
My child is deceased
How old is your child? If your child is 24 months, please choose 13-24 months. If your
child is older than 24 months but still 2, please choose the 2-4 option.
1-12 months
13-24 months
2-4 years
My child is older than 4 years
How many copies of the SMN2 gene does your child have? _______
Please select the treatments(s) your child has received.
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec-xioi)
None of the above
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If your child has not received either of these treatments, please select “none of the
above”.
If you would like to share information about your child, his/her treatment(s), quality of
life, etc. please use the space provided below. _______
As a token of our appreciation for taking this survey, we will have a raffle for a $50
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation.
If you are interested in entering the raffle, please enter your email below.
By providing your email you acknowledge that your answers to this survey may not be
anonymous. ____________________________.

81

APPENDIX J
SURVEY FOR PARENTS WHOSE CHILD IS DECEASED AT OLDER THAN 4
YEARS OF AGE
Are you the parent of a child with SMA?
If you are the parent of more than one child with SMA please take the survey 1 time for
each child.
Yes
No
We would like to provide you with questions that use the appropriate tense; is your child
with SMA living or deceased?
My child is living
My child is deceased
How old was your child when he/she passed away? If your child was 24 months, please
choose 13-24 months. If your child was older than 24 months but still 2, please choose
the 2-4 option.
1-12 months
13-24 months
2-4 years
My child was older than 4 years
How many copies of the SMN2 gene did your child have? _______
Please select the treatments(s) your child received.
Spinraza (nusinersen)
Zolgensma (onasemnogene abeparvovec-xioi)
None of the above
If your child did not receive either of these treatments, please select “none of the above”.
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If you would like to share information about your child, his/her treatment(s), quality of
life, etc. please use the space provided below. _______
As a token of our appreciation for taking this survey, we will have a raffle for a $50
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation.
If you are interested in entering the raffle, please enter your email below.
By providing your email you acknowledge that your answers to this survey may not be
anonymous. _____________________________.
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